BCLI
What one share of Brainstorm Cell Therapeutics holds
Biological Products, (No Diagnostic Substances)
Brainstorm Cell Therapeutics Inc. is a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”, also known as Lou Gehrig’s disease), progressive multiple sclerosis (“PMS”), Alzheimer’s disease (“AD”), and other neurodegenerative diseases.
Brainstorm Cell Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.95 |
|---|---|
| Cash and investments | $0.00 |
| Book value | −$1.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$4.00 | $0.08 | −$4.79 | — | $7.95 |
| 2017 | — | −$3.96 | $0.14 | −$2.03 | — | $4.65 |
| 2018 | — | −$10.46 | $0.28 | −$9.57 | — | $3.62 |
| 2019 | — | −$15.92 | $0.32 | −$8.03 | — | −$7.91 |
| 2020 | — | −$15.99 | $0.19 | −$17.88 | — | $15.13 |
| 2021 | — | −$10.14 | $0.14 | −$11.03 | — | $7.97 |
| 2022 | — | −$9.97 | $0.01 | −$7.95 | — | −$1.23 |
| 2023 | — | −$5.99 | $0.01 | −$7.13 | — | −$1.20 |
| 2024 | — | −$2.31 | — | −$1.81 | — | −$1.26 |
| 2025 | — | −$1.11 | — | −$0.75 | — | −$0.90 |